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The HIV-1 nucleocapsid protein (NC) has been hypothesized to be cleaved by the viral protease (PR) during early infection. Characterization
of viruses, with amino-acid substitutions that modulate PR cleavage of NC in vitro, was performed in cell culture. Two of the NC mutants, NCN17F
and NCN17G, had decreased infectivity and exhibited severe H9 replication defects. Examination of viral DNA after infections revealed defects in
reverse transcription and integration, although integration defects were cell-type dependent. However, while the defects in reverse transcription
and integration correlate with lowered infectivity in a single-round of infection, they did not approach the magnitude of the replication defect
measured in H9 cells over multiple rounds. Importantly, we fail to see evidence that H9 cells are re-infected with the NCN17G and NCN17F viruses
24 h after the initial infection, which suggests that the principal defect caused by these NC mutations occurs during late events of viral replication.
Published by Elsevier Inc.Keywords: HIV-1; Nucleocapsid; Protease; Viral DNA; Provirus; Mutant; Replication; Early infectionIntroduction
The human immunodeficiency virus type 1 (HIV-1)
nucleocapsid protein (NC) and its Zn2+-fingers are central to
many viral replication process including assembly (Berkowitz
et al., 1993, 1995, 1996; Cen et al., 1999) and infectivity
(Buckman et al., 2003; Darlix et al., 1995; Dorfman et al., 1993;
Rein et al., 1998). The NC protein originates as a domain in the
Pr55Gag and Pr160Gag-Pol precursors and is liberated as a mature
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doi:10.1016/j.virol.2006.07.011maturation (Henderson et al., 1992). HIV-1 NC contains two
essential and highly conserved Zn2+-finger structures with
invariantly spaced Cys and His residues of the form -Cys-X2-
Cys-X4-His-X4-Cys- that are very sensitive to mutagenic or
chemical alteration (Chertova et al., 1998, 2003; Gorelick et al.,
1990, 1999; Dorfman et al., 1993; Lapadat-Tapolsky et al.,
1993; Morcock et al., 2005; Rice et al., 1995; Tanchou et al.,
1998). A number of mutations have been made in NC that have
given researchers opportunities to examine the role of this
protein in viral replication, in infected cell systems. Of great
interest are amino acid residues that are highly conserved, such
as the Cys and His residues known to form the Zn2+-finger
structures. These structures have been shown to be critically
involved in a wide array of functions including, but not limited
to, recognition of the viral RNA during assembly and NC's
nucleic acid chaperone functions that occur throughout both the
reverse transcription (Aldovini and Young, 1990; Buckman et
al., 2003; Darlix et al., 1995; Gorelick et al., 1990, 1993, 1999;
Table 1
RT activity of mutant and wild-type HIV-1 from transfected 293T cells
Virus RT activity
(cpm of [3H]-TMP incorporated/mL) a
(−)-Control b 0
NCN17A 3.06±0.01×10
6 c
NCN17G 3.98±0.14×10
6
NCN17F 4.16±0.01×10
6
NCN17L 5.00±0.19×10
6
NCN17K 2.64±0.02×10
6
NCN17R
d 2.44±0.08×106
NCN17S
d 3.43±0.08×106
WT 3.55±0.04×106
a Values are from a representative experiment, corrected for a background
of 850±130 cpm [3H]-TMP in 0.1 mL of viral supernatant.
b (−)-Control is from 293T cells transfected with sheared salmon sperm DNA.
c Error reported is the standard deviation of two replicates.
d Mutation recovered after initial infection with virus containing containing
the NCN17G mutation (Tozser et al., 2006).
262 J.A. Thomas et al. / Virology 354 (2006) 261–270Levin et al., 2005; Rein et al., 1998) and integration processes
(Buckman et al., 2003; Carteau et al., 1997, 1999; Farnet and
Bushman, 1997; Gao et al., 2003; Thomas et al., in press).
In HIV-1 and SIV, there are a number of other highly
conserved residues within the invariant Zn2+-fingers, one of
them being an Asn located within the first loop of the NH2-
terminal Zn2+-finger of nearly all primate immunodeficiency
viruses (Kuiken et al., 2002). The reason that this Asn is so
highly conserved could be simply structural as this residue
has been proposed to interact with SL3 of the Ψ site and is
also involved in intraprotein stabilizing interactions (De
Guzman et al., 1998). Another possible reason for this
conservation is that NC may be cleaved after this residue by
the viral protease (PR) during early infection—Tozser et al.
(2004) have demonstrated the in vitro cleavage of recombi-
nant HIV-1 NC or NC peptides by PR after this conserved
Asn. Cleavage at this site in HIV-1 was suspected, as similar
NC fragments were earlier isolated from virion cores of
equine infectious anemia virus (EIAV), a related lentivirus;
these fragments were found to be a result of the EIAV PR
activity (Roberts et al., 1991; Roberts and Oroszlan, 1989). It
has been proposed that such cleavage may be important
during early infection of HIV-1. Additional support for this
hypothesis came from the observation that immunogold
labeling of NC after infection with murine leukemia virus
using antibodies against the amino- and carboxyl-terminus
showed that these fragments are localized in different areas of
the nucleus (Risco et al., 1995).
The role of PR during early infection, i.e., between initiation
of reverse transcription and integration, is controversial. It has
been reported that PR inhibitors act not only by blocking
maturation of virus particles, but can inhibit early events of viral
infection as well (Baboonian et al., 1991; Nagy et al., 1994;
Panther et al., 1999). The observed block occurred in MAGI
and H9 cells, and was detected by a large decrease in quantities
and stability of vDNA. Other groups have reported that PR
inhibitors have no effect during early infection in MT-4 cells
(Jacobsen et al., 1992) or MAGI cells (Kaplan et al., 1996;
Uchida et al., 1997). Possible reasons for the discrepancy
between published results include differences in the concentra-
tions of PR inhibitors used, the amount of virus used for
infections (multiplicity of infection), and the type of cells used
to assay the infections. Any of these differences could account
for the conflicting results.
This study examined how substitutions at Asn 17 in the
gene encoding NC (in the context of full-length HIV-1
proviruses) would affect virus replication. A set of structurally
and functionally divergent changes were made that had been
shown previously to modulate the in vitro Kcat/Km for PR
cleavage of NC (Tozser et al., 2004). Proviral clones were
transfected into 293T cells and the resulting viruses were
characterized for protein expression, polyprotein processing,
genomic RNA packaging, and single- and multiple-round
replication. In addition, reverse transcription and integration
were examined after infection with the NCN17A, NCN17F, and
NCN17G mutants in several different cell-types. The two
mutants that are most replication-defective (NCN17F, NCN17G)show only minor defects in reverse transcription, more
pronounced defects in integration, but surprisingly, these
reductions do not account for the >1000-fold reduction in the
replication titer in H9 and SupT1 cells.
Results
Viral particle analysis
To examine the effects of substitutions at the conserved
Asn 17 residue in NC on virus production and replication,
proviral plasmid constructs were transfected into 293T cells.
Viral supernatants were collected 48 and 72 h post-
transfection, clarified, and the RT activities of the virion
particles were measured (Table 1). The analysis shows that
the RT levels are quite similar for the NC mutants and wild-
type viruses. Thus, none of these mutations appear to affect
the production and release of virion particles.
The levels of viral proteins in these supernatants that were
pelletable at 112,000×g for 1 h were examined. Fig. 1A
shows immunoblots of samples using specific antiserum to
p7NC, p24CA, and gp120SU. All of the mutants have protein
and PR processing levels that are similar to the wild-type
virus. Thus, these mutations in NC do not appear to
significantly alter viral protein expression or the relative
Gag/Gag–Pol/Env ratios as the levels of proteins are clearly
similar to those of the wild-type virus after adjusting for
equivalent RT activities. There is a very slight difference in
the amount of Gag precursor processing between the mutant
and wild-type viruses, with slightly less unprocessed Pr55Gag
in the wild-type lane, as visualized with the two Gag antisera.
Note that there is a difference in the level of gp160Env
between all of the mutants and the wild-type viruses;
however, the levels of gp120SU are similar among all of the
viruses. It is not uncommon to see a large variability in the
levels of gp160Env in pelleted virus preparations derived from
transfections (unpublished results).
Fig. 1. Protein immunoblotting and Northern blot analyses of mutant and wild-
type samples. Virus samples were pelleted by ultracentrifugation from
transfected 293T cell supernatants. “(−)-Control” samples are supernatants
pelleted from 293T cells transfected with sheared salmon sperm DNA. (A) All
samples were adjusted to an equivalent RT activity level (2.2×106 cpm [3H]-
TMP incorporated/mL). Immunoblots were incubated consecutively with
antisera to p7NC (bottom panel), p24CA (middle panel), and gp120SU (top
panel). Molecular weight markers are presented on the left with the antiserum
used and the positions of the various proteins detected on the right. (B) RNA
samples isolated from viruses were adjusted for equivalent levels of RT activity
(3.6×107 cpm [3H]-TMP incorporated/mL). The RNAs were fractionated by
denaturing agarose gel electrophoresis, transferred to a nitrocellulose membrane
and probed with a [32P]-labeled 8088 bp Ava I, random primed pNL4-3
fragment. Various dilutions of wild-type virus and the size of the full-length
genomes are presented on the right.
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mutant and wild-type virus preparations. As can be seen in the
Northern blot in Fig. 1B, the mutants appear to package levels
of viral RNA that are quite similar to those found in the wild-
type virus. The levels of genomic RNA in the various viral
samples were also assessed by real time RT-PCR for HIV-1
(Gorelick et al., 1999), and results similar to those from the
Northern blot analysis were obtained (data not shown). There
appears to be no significant effect of these mutations on particle
formation, maturation, or RNA packaging. Therefore, the
infectivity of these mutants was next examined.Infectivity analysis of NC mutant virions
Numerous experiments were performed to determine
whether Asn 17 mutations in NC would affect the ability of
these viruses to infect permissive cells and propagate. Initially,
single round infectivity assays were performed to examine the
ability of these mutants to infect HCLZ cells and generate the
early gene product Tat. HCLZ cells contain the LacZ gene under
the control of an HIV-1 LTR. When the promoter in the LTR is
activated by Tat generated by the incoming virus, β-
galactosidase is produced and the cells turn blue in the presence
of 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal).
HCLZ cells were incubated with mutant and wild-type virus-
containing supernatants at various dilutions and the percent
wild-type infectivity (adjusting for equivalent RT activities) is
presented in Fig. 2A. The NCN17S mutant is as infectious as the
wild-type virus within experimental error, and the titers of the
remaining mutants are lower (P<0.01, Student's t test). Thus,
mutations of Asn 17 in NC result in the perturbation of single-
round infectivity titers; the NCN17G and NCN17F mutants are the
most defective, with reductions in titers of 2.2- and 3.9-fold,
respectively.
The ability of these NC mutants to replicate in H9 cells was
next assessed. Limiting dilution analysis of wild-type and
mutant viruses was performed and results are presented in Figs.
2B–E. The wild-type virus was able to spread throughout the
H9 culture, even when diluted 106-fold (Fig. 2B). The NCN17F
and NCN17G mutants were the most defective of all of the
mutants with limiting dilution titers of 100 and 102 tissue culture
infectious units (TCIU) per mL (Figs. 2C and D), respectively.
Thus, the titer for the NCN17F mutant was 10
6-fold lower than
wild-type. The NCN17A mutant was also tested (Fig. 2E) and
had a limiting dilution titer of 105 TCIU/mL. The remaining
mutants had titers between the NCN17A mutant and the wild-
type virus (data not shown). Note that the RT activity levels of
the starting inocula for the NCN17F or NCN17G mutants are 4- to
5-fold greater than that for the wild-type virus (Fig. 2, legend);
this indicates an even greater defect in replication for these
mutants compared to wild-type.
Because the NCN17F and NCN17G mutant viruses were
severely replication-defective in H9 cells, we tested their
ability, along with NCN17A, to support spreading infections in
SupT1 and CEMX174 cells. The limiting dilution titers for the
NCN17F and NCN17G mutants, determined in SupT1 cells,
showed the same magnitude decrease compared to wild-type
(Table 2) as was observed in H9 cells (Figs. 2B, C, and D).
Interestingly, the titers determined in CEMX174 cells showed
that the NCN17G replicated at the same level as wild-type, and
the NCN17F mutant had a titer only 10
3-fold lower than wild-
type (Table 2).
The genotypes of the proviruses isolated from the infected
H9 cultures were examined within the confines of the NC gene
to determine whether any reversions occurred. This was
performed by isolating total DNA from cells infected with the
wild-type, NCN17F, NCN17G, and NCN17A mutant viruses.
Samples were taken at 34 and 55 days postinfection, from the
greatest dilution that maintained a positive infectivity titer for
Table 2
Limiting dilution titers in SupT1 and CEMX174 cells
Virus Cell line
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were PCR amplified and sequenced as previously described
(Gorelick et al., 1999). For both the day-34 and day-55 harvests,Fig. 2. Single- and multiple-round infectivity analyses of mutant and wild-type
HIV-1. (A) For single-round infectivity assays, clarified supernatants from
transfected 293T cells were cultured with HCLZ cells and the percent wild-type
infectivity titers are presented. Titers have been corrected for equivalent levels of
RTactivities and are representative of four independent infectivity assays. (B–E)
For long-term, multiple-round, infectivity analysis of mutant and wild-type
viruses in H9 cells, supernatants from transfected cells 293Twere 10-fold serially
diluted and used to infect H9 cells. Viral replication was monitored by measuring
the RT activity in culture supernatants. (B) Wild-type virus and (−)-Control
samples. (C) NCN17F mutant virus. (D) NCN17G virus. (E) NCN17A virus. The
starting inocula for the viruses presented are 3.6×106, 1.7×107, 1.3×107, and
7.4×106 cpm of [3H]-TMP incorporated per mL RT activity for the wild-type,
NCN17F, NCN17G, and NCN17A viruses, respectively. Dilutions are (♦)—
undiluted, (▪)—1:101, (▴)—1:102, (●)—1:103, (⋄)—1:104, (□)—1:105,(▵)—1:106, and (○)—1:107. Undiluted “(−)—Control” supernatant (×).
SupT1 CEMX174
WT 1:10 7a 1:106
NCN17A 1:10
6 1:105
NCN17G 1:10
4 1:105
NCN17F 1:10
2 1:103
a Titers are determined by taking the greatest dilution that gave rise to a
spreading infection over the 8 week assay period. Positively infected cultures
were determined by RT activity in the culture supernatant. Initial RT levels for
input virus are 6,706,470 cpm/mL for wild-type (WT), 11,260,400 cpm/mL for
NCN17A, 7,521,370 cpm/mL for NCN17G, and 6,736,500 cpm/mL for NCN17F.all mutant viral cultures maintained the original NC genotypes
that were used to infect the H9 cultures.
Viral DNA production and analysis
In order to determine whether the significant replication
defects of the NCN17F and NCN17G mutant viruses occurred
during early infection events, viral DNA (vDNA) synthesis was
analyzed in these as well as the NCN17A and wild-type viruses.
Initially, viruses pseudotyped with the VSV-G Env (Burns et al.,
1993) were used to infect human osteosarcoma cells (HOS)
(McAllister et al., 1971). This system has advantages that the
infection is limited to a single round, infectious titer is boosted
(due to VSV-G envelope), and contaminating plasmid DNA
can easily be removed by washing as the HOS cells are
adherent. Transfections with the proviral plasmid coding for the
RTD185K/D186L mutant virus (Gorelick et al., 1999) were per-
formed for each infection experiment to assess the levels of
contaminating carryover plasmid DNA.
At 24 h postinfection, total cellular DNA was isolated and
samples were examined for levels of specific vDNA target
sequences synthesized during the course of reverse transcrip-
tion. These targets include early (R-U5) and late (R-5′UTR)
reverse transcription intermediates, proviruses (Alu-LTR), and
the following 2-LTR circular vDNA targets: (i) full-length 2-
LTR circle junction (FJ) targets, which provide a measure of the
levels of linear vDNAs that were completely synthesized prior
to being ligated, and (ii) total 2-LTR junction (TOTAL) targets,
which encompass partial as well as complete (or FJ) LTR
junction fragments (Buckman et al., 2003).
The NCN17F and NCN17G mutants, although quite replica-
tion-defective, are surprisingly infectious in HOS cells, as
quantities of early and late reverse transcription intermediates
(R-U5 and R-5′UTR, respectively) are only ∼2-fold lower than
wild-type (Table 3). The most likely reasons for the reductions
are that the vDNA synthesized from infections with these
mutant viruses is less stable, or that there may be a minor defect
in reverse transcription initiation. Examination of the efficiency
of reverse transcription (i.e., progression of reverse transcription
once it has commenced) reveals that NCN17G and NCN17F are
not significantly different from wild-type virus (Table 3). There
is no apparent effect of these two NC mutations on integration
efficiency in the HOS cells (Table 3). Examination of the
Table 3
vDNA analysis 24 h postinfection of HOS, HeLa-CD4(+), and H9 cells with mutant or wild-type virus
Cell line and Env a Virus R-U5
(% WT) b
R-5′UTR
(% WT) c
Provirus
(% WT) d
TOTAL 2-LTR
circles (% WT) e
Reverse transcription
efficiency (% WT) f
Integration efficiency
(% WT) g
% FJ/TOTAL
2-LTR circles h
HOS and
VSV-G/Env(+) virus i
WT 100 100 100 100 100 100 29±1.3
NCN17A 40±8.0 54±9.2 68±27 140±5.4 100±26 120±28 34±0.3
NCN17G 43±13 52±11 55±14 130±16 150±47 110±20 62±1.3
NCN17F 64±3.4 57±4.7 48±5.9 90±12 170±42 84±9.0 54±6.5
HeLa-CD4(+)
and Env(+) virus j
WT 100 100 100 100 100 100 12±3.5
NCN17A 42±4.2 48±3.5 58±16 45±6.2 110±2.9 120±26 15±2.1
NCN17G 36±0.6 34±1.1 26±2.0 56±2.2 97±4.8 74±3.3 24±3.0
NCN17F 23±3.2 21±1.6 14±5.2 32±2.2 96±6.8 69±29 29±8.2
H9 and Env(+) virus i WT 100 100 100 100 100 100 13±1.1
NCN17A 81±16 90±5.9 96±22 110±14 110±7.7 110±30 20±1.4
NCN17G 56±14 50±11 23±13 95±30 87±8.8 37±14 12±4.6
NCN17F 51±15 43±8.8 12±4.2 99±0.1 82±3.9 22±6.6 22±1.5
a “Cell line” indicates the line that was used for the infections and “Env” refers to the envelope(s) on the virus. Env(+) indicates HIV-1 Env expression from the
provirus and VSV-G indicates pseudotyped virus. Note that the presence of HIV-1 Env in the pseudotyped virus has no effect on VSV-G mediated infections (data not
shown).
b Quantitites of R-U5 expressed as a percentage of wild-type for each cell type; 100%=1.0×106 copies from 3.4×102 infected HOS, 2.0×105 copies from 2.4×104
infected HeLa-CD4(+), and 5.6×104 copies from 6.9×104 infected H9 cells.
c Quantitites of R-5′UTR expressed as a percentage of wild-type for each cell type; 100%=5.3×105 copies from 3.4×102 infected HOS, 1.3×105 copies from
2.4×104 infected HeLa-CD4(+), and 2.8×104 copies from 6.9×104 infected H9 cells.
d Quantities of Provirus expressed as a percentage of wild-type for each cell type; 100%=3.1×105 copies from 3.4×102 infected HOS, 1.2×104 copies from
2.4×104 infected HeLa-CD4(+), and 6.0×103 copies from 6.9×104 infected H9 cells.
e Quantities of TOTAL 2-LTR circles expressed as a percentage of wild-type for each cell type, 100%=8.7×103 copies from 3.4×102 infected HOS, 3.3×103 copies
from 2.4×104 infected HeLa-CD4(+), and 1.9×102 copies from 6.9×104 infected H9 cells.
f Reverse transcription efficiency was calculated by taking the ratio of late (R-5UTR) to early (R-U5) reverse transcripts for each infection and reporting it as a
percentage of the wild-type ratio.
g Integration efficiency was calculated by taking the ratio of provirus (Alu-LTR) to late reverse transcripts for each infection and reporting it as a percentage of the
wild-type ratio.
h “% FJ/TOTAL 2-LTR Circles” reports the level of full-junction 2-LTR circles (FJ) as a percentage of total 2-LTR circles (TOTAL).
i Results reported as the means from 3 separate infection experiments± the standard error of the mean.
j Results reported as the means from 2 separate infection experiments± the standard error of the mean.
265J.A. Thomas et al. / Virology 354 (2006) 261–270conversion of late reverse transcription intermediates to total 2-
LTR circular products (R-5′UTR and TOTAL 2-LTR circles,
respectively; Table 3) reveals that the NCN17G and NCN17F
mutations do increase the relative amounts of circles by ∼2-
fold. Interestingly, the ratio of FJ to TOTAL 2-LTR circles is
also higher in these mutant infections indicating that there may
be a minor inhibition of integration.
Remarkably, analysis of vDNA from HOS cell infections
with VSV-G pseudotyped virus did not show any defects large
enough to explain the 103 to 105-fold reduction in titers
measured in H9 cells (Figs. 2C–D). However, these results can
explain why these mutants had a 2 to 3-fold reduction in
infectious titer in HCLZ cells; vDNA quantities were 2- to 3-
fold lower in the mutants when compared to wild-type
infections. The reason for the differences between H9 and
HOS cell infections could be due to cell-type specific effects or
because the viruses used to infect the HOS cells were
pseudotyped with VSV-G. It is well-established that VSV-G
pseudotyping can permit infection by HIV-1 mutants that are
normally blocked prior to initiation of reverse transcription
(Aiken, 1997; Kaushik and Ratner, 2004).
These issues were addressed by performing parallel experi-
ments, examining vDNA from HeLa-CD4(+) and H9 cells
infected with gp120SU containing Env(+) viruses and theseresults are also shown in Table 3. The results from HOS cells
with vDNA profiles obtained after infection of HeLa-CD4(+) or
H9 cells are very similar. Specifically, (i) mutant virus infections
revealed quantities of R-U5 and R-5′UTR that were lower that
wild-type, (ii) efficiencies of reverse transcription were similar
to wild-type, and (iii) conversion of R-5′UTR to TOTAL 2-LTR
circles and the ratio of FJ to TOTAL 2-LTR circles were
elevated compared to wild-type. In addition, in HOS and HeLa-
CD4(+) cells, the integration efficiencies for the NCN17F and
NCN17G were the same as wild-type virus (Table 3). In contrast
to this, we observed that, in H9 cells, the efficiency of
integration was significantly lower for NCN17G and NCN17F
(P<0.05, Student's t test) than for wild-type or NCN17A
infections (Table 3). However, the magnitude of this decrease
was only ∼5-fold lower than wild-type. This indicated that the
choice of cell-type used for infections was more important than
the choice of the envelope protein used, but even the integration
defect does not fully account for the enormous reduction in titer
observed in H9 cells (Figs. 2C–D).
Other steps that could account for the large reduction in H9
replication with the mutants are late events of infection
(assembly, RNA packaging, or maturation). Because the viruses
used to infect H9 cells were Env(+), the initial infections would
give rise to spreading infections as the proviruses generated can
Fig. 3. Change in vDNA quantities from 24 to 48 h postinfection. The change in
R-U5 (A) or R-5′UTR (B) was calculated by dividing the respective vDNA
quantities at 48 h by vDNA quantities at 24 h and expressed as a percentage.
Multiple-round infections were in H9 cells infected by Env(+) viruses (white
bars). Single-round infections were in HOS cells infected with VSV-G
pseudotyped Env(+) viruses (black bars). Results presented are the averages of
2 (H9 infections) or 3 (HOS infections) separate transfection–infection
experiments and error bars represent the standard error of the mean.
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quantities at 24 and 48 h postinfection, when viruses generated
during the initial round of infection are re-infecting the H9 cells
(Butler et al., 2002; Kim et al., 1989). In a multiple-round
infection with wild-type virus, quantities of reverse transcrip-
tion intermediates were 2- to 3-fold higher at 48 h than at 24 h
postinfection (Fig. 3). In contrast to this, in a single-cycle
infection of HOS cells with wild-type virus, quantities at 48 h
were about 50% of 24 h quantities (Fig. 3). A similar result was
obtained after infection with NCN17A in both multiple- and
single-round infections (Fig. 3) in agreement with having a
replication phenotype similar to wild-type (Figs. 2B and E,
Table 2). When H9 cells were infected with the most replication
defective mutant, NCN17F, quantities of early and late reverse
transcription intermediates at 48 h were approximately 60%
quantities at 24 h postinfection (Fig. 3); this relative difference
was the same as that observed during a single-round infection
(Fig. 3). The NCN17G mutant, which was less replication-
defective than the NCN17F mutant, also showed lower quantities
of late product at 48 h, but quantities of early product were
approximately the same at 24 and 48 h (Fig. 3). These quantities
are slightly higher than what was observed from a single-cycle
infection indicating that some re-infection was occurring. Thus,
these results indicate that the NCN17F and NCN17G mutations
apparently have more pronounced effects during the late events
of infection in H9 cells than during the early infection events.
Discussion
This study was performed to assess the impact of amino acid
substitutions at position 17 of NC on HIV-1 infection and
replication. This residue is highly conserved as it is present in
over 97% of HIV-1, HIV-2, and SIV sequences reported through
2002 (Kuiken et al., 2002). The reason why this position must
be an Asn is not obvious but it may be a constraint imposed by
the zinc-finger structure. Interestingly, it is also a site where, in
vitro, the HIV-1 PR can cleave apo-NC (Tozser et al., 2004) and
this cleavage was proposed to be important for completion of
reverse transcription or integration. This possibility is con-
troversial as some groups have reported inhibition of early steps
in viral infection by PR inhibitors (Baboonian et al., 1991; Nagy
et al., 1994; Panther et al., 1999) while other groups have
reported no effect of protease inhibitors on early infection
(Jacobsen et al., 1992; Kaplan et al., 1996; Uchida et al., 1997).
Importantly, it has been demonstrated that fragments of NC can
catalyze many of the chaperone functions that full-length NC
can perform (Beltz et al., 2004). The substitutions examined in
this study include those that either increased (NCN17F, NCN17L,
NCN17A) or decreased (NCN17G, NCN17K) the Kcat/Km of PR
cleavage of NC in cell-free systems (Tozser et al., 2004). If PR
does cleave NC at this site, one would expect to see defects in
replication that would be apparent during early infection events.
Mutant viruses were examined in HCLZ assays and the Phe
and Gly substitutions showed the greatest effect on infectivity,
compared to wild-type, with reductions of 3.9- and 2.2-fold,
respectively. The other substitutions only affected infection
minimally (Fig. 2A). It is important to note that a positiveinfectivity measured using HCLZ or MAGI cells is not an
indication that integration has occurred, as Tat can be expressed
from unintegrated vDNA (Gorelick et al., 1999; Wu et al., 1999;
Wu, 2004). This result does indicate that the vDNA leading to
the production of Tat is synthesized in abundant quantities
during infection, but integration may still be affected.
The mutations were then assayed for their ability to replicate
in H9 cells over multiple-rounds; compared to wild-type, the
NCN17F mutant showed a reduction in titer of ∼106-fold while
the NCN17G mutation reduced the titer by ∼103-fold. The other
substitutions did not affect the ability of the virus to replicate
(Fig. 2B). Comparative replication assays performed in SupT1
cells showed similar reductions in titer with the NCN17F and
NCN17G mutants (Table 2). Interestingly, replication assays
267J.A. Thomas et al. / Virology 354 (2006) 261–270performed in CEMX174 cells showed a 102-fold reduction in
titer for the NCN17F mutant and no defect for the NCN17G mutant
(Table 2). The reasons for this could be because CEMX174
were generated by fusion of T and B cells, and, as these cells
adhere to one another strongly upon division, infection appears
to be more efficient. Importantly, in both of the T-cell lines
examined (H9 and SupT1), similar magnitude reductions in titer
were observed. If NC is cleaved during early infection, one
would expect that the observed reduction in titer would be
reflected by a profound reduction in integration.
The quantities of vDNA synthesized and integrated after
24 h of infection in HOS, HeLa-CD4(+), and H9 cells were
examined (Table 3). In all cell-types, quantities of R-U5 were
∼2-fold lower than wild-type, but reverse transcription
efficiencies were at least as high as that for wild-type infections.
Examination of proviruses revealed that integration was
inhibited the greatest (∼5-fold) with the NCN17F or NCN17G
mutant viruses in H9 cells only. This result is interesting in that
this reduction does not approximate the 103 to 106-fold
reduction in titer observed in the H9 replication assays. It
should be noted that there may be differences between the
replication-defective and replication-competent viruses in this
study that are not detected with the assays currently employed
by this and other laboratories.
Considering the in vitro rates of cleavage for the mutant NC
sequences examined by Tozser et al. (2004), the measured
kinetic parameters correlate with the infectivity characteristics
observed in this study. In other words, in NC mutants where the
kinetic parameters of NC cleavage are similar to wild-type NC
(Km values ranging from 0.17 to 0.86 mM for the NC-1
cleavage reported in Tozser et al., 2004), the infectivities in H9
cells are similar (e.g., the NCN17A, NCN17L and NCN17K
mutants). Viruses containing mutant NC proteins with divergent
kinetics of cleavage compared to the wild-type NC (Km values
that are more than 3-fold higher or lower than the wild-type Km)
are defective in both single- and multiple-round infectivity
assays (NCN17F and NCN17G). Although the phenotype of these
mutants correlate with reported kinetic parameters, the results of
this study do not provide support for a required cleavage of NC
after Asn 17 by PR during early infection. It should be noted
that the NC protein is exquisitely sensitive to chemical or site
directed alteration (Aldovini and Young, 1990; Arthur et al.,
1998; Chertova et al., 1998, 2003; Dorfman et al., 1993; Goel et
al., 2002; Gorelick et al., 1990, 1993, 1999; Morcock et al.,
2005; Rice et al., 1997; Tanchou et al., 1998; Turpin et al.,
1999). Thus, the defects in replication observed in the NCN17F
and NCN17G mutant viruses could be due to unrelated effects of
the mutations such as deleterious protein conformational
changes that would be in addition to effects on the putative
PR cleavage of NC.
What is apparent is that the replication defects of the NCN17F
mutant most probably occur after integration, during the late
steps of viral replication (assembly, budding, maturation). In
support of this, when vDNA quantities were examined at 48 h
postinfection of H9 cells with NCN17F, no re-infection events
could be detected (Fig. 3). The NCN17G mutant shows some
evidence for re-infection (Fig. 3) in agreement with a lessreplication-defective phenotype in H9 and SupT1 cells. Thus,
the mutant proviral clones can form infectious virus particles
upon transfection of 293T cells, but apparently not after
infection of H9 cells. It is still possible that PR is necessary
for early infection events but it is unlikely that cleavage after
Asn 17 in NC is the target. Interestingly, PR has also been
shown to cleave CA of HIV-1 in vitro and of Mason-Pfizer
monkey virus in vitro and in cells (Rumlova et al., 2003; Tozser
et al., 2003). The present study does show a cell-type-specific
response to HIV-1 infection, and indicates that the cell line
chosen is critical for any study.
Materials and methods
Cell lines and plasmids
H9 (Popovic et al., 1984), SupT1 (Smith et al., 1984),
CEMX174 (Salter et al., 1985), 293T (293 cell line expressing
the simian virus 40 large T antigen; Gorelick et al., 1996),
HCLZ (CD4 producing HeLa cells containing an HIV-1 LTR/
β-galactosidase construct; Gorelick et al., 1993), HOS
(Buckman et al., 2003; Julias et al., 2001; McAllister et al.,
1971), and HeLa-CD4(+) clone 1022 (designated HeLa-CD4(+),
AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH: from Dr. Bruce Chesebro; Chesebro et al.,
1990, 1991; Chesebro and Wehrly, 1988) cell lines were used.
Infection of the various cell lines with virus containing
supernatants was performed in the presence of 2 μg/mL
hexadimethrine bromide (Polybrene; Sigma, St. Louis, MO) to
reduce electrostatic repulsion between the virus and cell
membranes and increase viral infectivity. All cultures were
maintained at 37 °C in 5% CO2. The pNL4-3 plasmid
(GenBank accession number AF324493) was obtained through
the AIDS Research and Reference Reagent Program, Division
of AIDS, NIAID, NIH: from Dr. Malcolm Martin (Adachi et
al., 1986). Viruses were generated by transfection of mutant
and wild-type pNL4-3 using TransIT-293 Transfection Reagent
(Mirus Corporation, Madison, WI) in accordance with
manufacturer's instructions. Culture fluids were harvested
48 h post-transfection, and the cell-free supernatants were
analyzed for virus. For quantitation of reverse transcription
intermediates (see below), proviral DNA clones were trans-
fected into 293T cells by CaPO4 coprecipitation and virus was
harvested as described (Buckman et al., 2003).
Site-specific mutagenesis of the gene coding for pNL4-3 NC
was performed using the Stratagene Quick Change Mutagenesis
Kit (La Jolla, CA). Substitution of specific nucleotides in the
NC coding region of the pNL4-3 plasmid is as follows:
NCN17F-a1969t/a1970t, NCN17G-a1969g/a1970g/t1971a,
NCN17A-a1969g/a1970c/t1971c, NCN17L-a1969t/a1970t/
t1971a, NCN17S-a1969t/a1970c/t1971a, NCN17K-t1971a,
NCN17R-a1970g/t1971a.
Viral protein analysis
Revere transcriptase (RT) assays were performed on clarified
supernatants, as previously described (Gorelick et al., 1990).
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described (McGrath et al., 2003) using the following antisera:
a mouse monoclonal antibody against gp120SU (AVP 3F5-D5-
F8 at a 1:1000 dilution), a goat anti p24CA (AVP goat # 81,
bleed 000805 at a 1:10,000 dilution), and a goat anti p7NC (AVP
goat # 77, bleed 000803 at a 1:5,000 dilution). Proteins were
visualized with X-ray film by chemiluminescence using the
BioRad Laboratories' (Hercules, CA) Immune-Star HRP
Substrate Kit and horseradish peroxidase conjugated to the
appropriate secondary antibody (BioRad).
Viral genome analysis
The full-length genomic RNA content of the wild-type and
mutant virus samples, adjusted for equal RT content, was
examined by Northern blotting as previously described
(Gorelick et al., 1990). Radiolabeled filters were analyzed
using BioRad Laboratories' Personal Molecular FX Phosphor-
imager with the Imaging Screen K and Quantity One software.
Limiting dilution infectivity assays
H9 cells (1×106) were incubated at 37 °C with 1 mL of
freshly harvested and clarified, undiluted and 10-fold serially
diluted supernatants from 293T-transfected cells as described
(Gorelick et al., 1990, 1993, 1999). After 24 h, an additional
1 mL of media was added and cells were cultured in 24-well
plates. Twice weekly, one-half of the culture suspension was
removed and replaced with fresh media containing 2 μg/mL
Polybrene, and weekly samples were taken for RT analysis
(see above) to monitor virus spread. Limiting dilution
infectivity assays in SupT1 and CEMX174 cells were
performed as described for H9 cells. Similarly, HCLZ cells
were infected with freshly harvested and clarified, serially
diluted supernatants from 293T-transfected cells and pro-
cessed as previously described (Gorelick et al., 1999;
McGrath et al., 2003).
Quantitation of vDNA species after infections
Apart from infections of H9 cells, procedures were followed
as previously described (Buckman et al., 2003). Briefly,
clarified supernatants from CaPO4 transfected 293T cells were
applied to 100 mm dishes containing 5×105 HOS cells/dish or
1×106 HeLa-CD4(+) cells/dish. Infected HOS and HeLa-
CD4(+) cells were harvested at 24 h postinfection, total cellular
DNAs were isolated using the Qiagen Blood Mini Kit
(Valencia, CA), and reverse transcription intermediates were
quantitated by real-time PCR. For infections of H9 cells,
clarified supernatants were added to 3×106 H9 cells per well in
a 6 well-plate, and 4 h postinfection virus was removed by
isolating H9 cells on a Ficoll-Hypaque pad (Ficoll-Paque Plus,
Amersham Biologicals, Piscataway, NJ), washed once with
phosphate-buffered saline, and cultured in the designated media
(see above). The cells were harvested at 24 or 48 h postinfec-
tion, and total cellular DNA was isolated as above. The copy
numbers acquired were adjusted for (i) equivalent RT activitiesof the inoculum generated by transfection and (ii) the number of
infected cells recovered (determined by quantifying the CCR5
gene; Thomas et al., in press) from which the total DNA
samples were derived. The Alu-LTR PCR for quantitation of
proviruses was performed as described (Thomas et al., in press).
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